-
1.发明公开4베타-(아미노메틸카르보닐)-4'-0-데메틸-4-0-에피-포도필로톡신 화합물, 이의 제조 방법 및 이를 포함하는 항암제 조성물 失效4 - （氨甲基羰基）-4'-O-去甲基-4-O-表 - 葡萄先导毒素化合物及其制备方法和包含其的抗癌组合物
公开(公告)号：KR1019980038758A
公开(公告)日：1998-08-05
申请号：KR1019960057686
申请日：1996-11-26
Applicant: 한국화학연구원
IPC: C07D493/04
Abstract: 본 발명은 수용성이 우수하고 암세포의 성장을 억제하는 효과를 나타내어 항암제로 사용가능한 하기 일반식 (I)의 4β-(아미노메틸카르보닐)-4'-O-데메틸-4-O-에피-포도필로톡신 화합물, 이의 제조 방법 및 이를 포함하는 항암제 조성물에 관한 것이다.
-
公开(公告)号：KR1019970021074A
公开(公告)日：1997-05-28
申请号：KR1019950035587
申请日：1995-10-16
Applicant: 한국화학연구원
IPC: C07D405/06
Abstract: 본 발명은 수용성이 우수하고 암세포의 성장 억제 효과를 나타내어 항암제로 사용 가능한 일반식(I)의 에피잔타틴의 아민 화합물, 이의 제조방법 및 이를 포함하는 항암제 조성물에 관한 것이다.
상기 식에서 X는 0, S, CR 또는 NR이고; R은 수소 원자 또는 저급 알킬기이고; n은 0 내지 2의 정수를 나타내며; 11번 탄소의 입체 화학은 R 또는 S이다.-
公开(公告)号：KR100327155B1
公开(公告)日：2002-03-13
申请号：KR1019990051200
申请日：1999-11-18
Applicant: 한국화학연구원
IPC: A61K31/425
Abstract: 본발명은하기화학식 1로표시되는화합물 KR-15012를함유하는항암제에에관한것이다. 상기화학식 1의 KR-15012을함유하는항암제는다양한인체기원의암세포주에대해증식및 생장억제활성이우수하며, 다약제내성을보이는암세포에대해서도우수한효과를보이기때문에암 치료제로서유용하게사용될수 있다.
-
公开(公告)号：KR1019960015969B1
公开(公告)日：1996-11-25
申请号：KR1019930009154
申请日：1993-05-26
Applicant: 한국화학연구원
IPC: C07J17/00
Abstract: The novel anti-tumor limonoid, 12-hydroxyamoorastatone, is prepared by : extracting minced barks of Melia azedarach var. with methanol; separating Acetic ethyl(EtOAc) and water; confirming the obtd. active fractions of acetic ethyl and water fractions with silica gel chromatography, and RP-reverse phase chromatography successively; and finally purifying the limonoid by recycling prep. HPLC.
Abstract translation: 通过以下方法制备新型抗肿瘤类柠檬醛，即12-羟基维生素A：提取Melia azedarach var。 用甲醇; 分离乙酸乙酯（EtOAc）和水; 证实了这一点。 依次用硅胶色谱法和RP-反相色谱法分离乙酸乙酯和水， 最后通过回收制剂净化柠檬醛。 HPLC。
-
-
Patent Agency Ranking
公开(公告)号：KR1020030005787A
公开(公告)日：2003-01-23
申请号：KR1020010041239
申请日：2001-07-10
Applicant: 한국화학연구원
IPC: A61K31/165
Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.
Abstract translation: 目的：提供能够有效地用作有效的抗氧化剂和抗癌剂的含有对人类癌细胞具有优异抗癌活性的粘液素-A的药物组合物，以及优异的抗氧化活性为主要成分。 构成：药物组合物含有通过与粘液细菌分离或化学合成或半合成获得的式1的粘液素-A。 通过以下步骤纯化粘液素-A：通过在吸收树脂存在下培养球状球形细菌菌株作为粘液细菌分离生物质和吸收树脂并离心培养液; 加入有机溶剂，优选丙酮和甲醇的混合溶剂; 提取和过滤除去生物质和吸收树脂; 通过减压浓缩滤液并在有机溶剂中萃取粗提取物制备活性级分; 并依次进行硅胶液相色谱和再循环制备型HPLC。
-
公开(公告)号：KR1020010047127A
公开(公告)日：2001-06-15
申请号：KR1019990051200
申请日：1999-11-18
Applicant: 한국화학연구원
IPC: A61K31/425
Abstract: PURPOSE: An anticancer drug containing a compound KR-15012 is provided, which has anticancer activity better than or equal to doxorubicin and excellent anticancer effect against cancer cell strains exhibiting resistance to conventional anticancer drugs such as doxorubicin and cisplatin. CONSTITUTION: An anticancer drug containing a compound KR-15012 represented by the formula 1 or salts thereof. The anticancer drug exhibits excellent anticancer effect against a cancer cell selected from the group consisting of A-549, SK-OV-3, SK-MEL-2, XF498 and HCT15, DCT15/ADM, A2780 and CP70.
Abstract translation: 目的：提供含有化合物KR-15012的抗癌药物，其具有优于或等于多柔比星的抗癌活性，并且对抗多种抗癌药物如多柔比星和顺铂的癌细胞株具有优异的抗癌作用。 构成：含有式1化合物KR-15012或其盐的抗癌药。 抗癌药对选自A-549，SK-OV-3，SK-MEL-2，XF498和HCT15，DCT15 / ADM，A2780和CP70的癌细胞表现出优异的抗癌作用。
-
8.发明公开4'-오-데메틸-에피포도필로톡신-베타-디-글루코시드의새로운아세탈유도체,이의제조방법및이를포함하는항암제조성물 失效新型缩醛衍生物4'-o-demethyl-epi-grape pilotoxin-beta-di-glucoside及其制备方法和含有它们的抗癌组合物
-
-
公开(公告)号：KR100424392B1
公开(公告)日：2004-03-24
申请号：KR1020010041239
申请日：2001-07-10
Applicant: 한국화학연구원
IPC: A61K31/165
Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.
Abstract translation: 目的：提供一种药物组合物，其含有对人癌细胞具有优异的抗癌活性以及优异的抗氧化活性作为主要组分的粘液溶血素A，其可以有效地用作有效的抗氧化剂和抗癌剂。 组成：药物组合物含有通过从粘细菌分离或化学合成或半合成获得的式1的粘多糖蛋白-A。 通过在吸附树脂存在下离心培养溶液培养作为粘细菌的粘细菌属细菌菌株来分离生物质和吸附树脂，纯粹分离粘液粘连素-A; 加入有机溶剂，优选丙酮和甲醇的混合溶剂; 提取并过滤去除生物质和吸收树脂; 通过在减压下浓缩滤液并在有机溶剂中萃取粗提取物来制备活性部分; 并连续进行硅胶液相色谱和再循环制备型HPLC。
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.016 seconds)
